MODELING MIGRAINE DAY FREQUENCY BY RESPONDER STATUS: A RE-ANALYSIS OF DATA FROM ERENUMAB CLINICAL TRIALS

被引：0
|
作者：
Porter, J. K. [1 ]
Burns, D. [2 ]
Di Tanna, G. L. [1 ]
Lipton, R. B. [3 ]
Palmer, S. [4 ]
Sapra, S. [5 ]
Villa, G. [1 ]
机构：
[1] Amgen Europe GmbH, Zug, Switzerland
[2] BresMed Hlth Solut Ltd, Sheffield, S Yorkshire, England
[3] Albert Einstein Coll Med, Bronx, NY 10467 USA
[4] Univ York, York, N Yorkshire, England
[5] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.2274
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PRM154
引用
收藏
页码：S382 / S382
页数：1
相关论文
共 50 条
  • [1] PARAMETRIC MODELLING OF MIGRAINE DAY FREQUENCY IN MIGRAINE PREVENTION: A CASE STUDY OF ERENUMAB CLINICAL TRIAL DATA
    Porter, J. K.
    DiTanna, G. L.
    Villa, G.
    Brennan, A.
    Palmer, S.
    Lipton, R. B.
    Jansen, J. P.
    Shah, N.
    Desai, P.
    Sapra, S.
    VALUE IN HEALTH, 2017, 20 (09) : A733 - A733
  • [2] Data sharing and re-analysis for randomised clinical trials in journals with a strong data sharing policy
    Naudet, F.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2018, 32 : 12 - 12
  • [3] MODELING MIGRAINE DAY FREQUENCY USING THE BETA-BINOMIAL DISTRIBUTION: A CASE STUDY OF ERENUMAB AS MIGRAINE PROPHYLAXIS
    Porter, J. K.
    Brennan, A.
    Palmer, S.
    Sapra, S.
    Shah, N.
    Desai, P.
    Villa, G.
    Lipton, A. B.
    VALUE IN HEALTH, 2017, 20 (05) : A329 - A329
  • [4] Risk and treatment effect heterogeneity: re-analysis of individual participant data from 32 large clinical trials
    Kent, David M.
    Nelson, Jason
    Dahabreh, Issa J.
    Rothwell, Peter M.
    Altman, Douglas G.
    Hayward, Rodney A.
    INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2016, 45 (06) : 2075 - 2088
  • [5] Re-analysis of previous meta-analysis of clinical trials of homeopathy
    Ernst, E
    Pittler, MH
    JOURNAL OF CLINICAL EPIDEMIOLOGY, 2000, 53 (11) : 1188 - 1188
  • [6] Re-analysis of the current status of clinical trial registration in China
    Li, Shuwen
    Li, Jianhao
    Zeng, Wenjing
    Li, Zhicheng
    Zhang, Jietong
    Wang, Siying
    Xu, Nenggui
    Li, Zeli
    FRONTIERS IN MEDICINE, 2025, 11
  • [7] Informative priors or noninformative priors? A Bayesian re-analysis of binary data from Macugen phase III clinical trials
    Chen, Ding-Geng
    Ting, Naitee
    Ho, Shuyen
    COMMUNICATIONS IN STATISTICS-SIMULATION AND COMPUTATION, 2017, 46 (06) : 4535 - 4546
  • [8] Migraine Polygenic Risk Score Is Associated with Severity of Migraine - Analysis of Genotypic Data from Four Placebo-controlled Trials of Erenumab
    Mikol, Daniel D.
    Picard, Hernan
    Klatt, Jan
    Wang, Andrea
    Peng, Cheng
    Stefansson, Kari
    NEUROLOGY, 2020, 94 (15)
  • [9] PRODUCTIVITY LOSSES AMONG PATIENTS WITH MIGRAINE: AN ANALYSIS OF ERENUMAB CLINICAL TRIAL DATA
    Porter, J. K.
    Di Tanna, G. L.
    Lipton, R. B.
    Sapra, S.
    Villa, G.
    VALUE IN HEALTH, 2018, 21 : S13 - S13
  • [10] ESTIMATING PATIENT UTILITY IN MIGRAINE: LONGITUDINAL ANALYSIS OF ERENUMAB CLINICAL TRIAL DATA
    Di Tanna, G. L.
    Porter, J. K.
    Lipton, R. B.
    Hatswell, A. J.
    Sapra, S.
    Villa, G.
    VALUE IN HEALTH, 2018, 21 : S225 - S225
12345